



21 August 2015

The Company Announcements Platform

ASX Limited

By E-lodgement

Proposed Grant of Options to Non-Executive Directors

Prescient Therapeutics (ASX: PTX) advise that the Board of Directors propose to seek shareholder approval at the Company's upcoming 2015 Annual General Meeting in relation to the proposed grant of options to Non-executive Directors of the Company. Consistent with industry norms, the granting of long term incentives as options, was agreed with the three Non-Executive Directors when they were appointed in November 2014. Over past months, the company has undertaken a benchmarking exercise and is comfortable that these allocations are appropriate. It is noted that the CEO and Managing Director has a separate agreement with the company for options, and that to date Mr Paul Hopper has declined participation in the option scheme. The proposed terms of the options are noted below:

A total of 300,000 unlisted options exercisable at \$0.085 (8.5 cents) per option to the Chairman of the Board being Mr Steven Engle, vesting in 3 tranches as noted below:

- 150,000 options vesting the day following the next general meeting of shareholders of the company (the Grant Date).
- 75,000 options vesting on the 12 month anniversary of the Grant Date.
- 75,000 options vesting on the 24 month anniversary of the Grant Date.

A total of 200,000 unlisted options exercisable at \$0.085 (8.5 cents) per option for each of the Non-executive Directors being Dr James Campbell and Mr Steven Yatomi-Clarke, vesting in 3 tranches as noted below:

- 100,000 options issued within 5 days of the next general meeting of shareholders of the company (the Grant Date).
- 50,000 options vesting on the 12 month anniversary of the Grant Date.
- 50,000 options vesting on the 24 month anniversary of the Grant Date.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or

persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials have been funded in part by grants from the U.S. Government, including the U.S. National Cancer Institute. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Dr Robert Crombie
Managing Director
+61 (0) 3 9982 4563

Paul Hopper
Executive Director
+61 406 671 515

Rudi Michaelson
Monsoon Communications
+61 (0) 3 9620 3333

